Table 1. Proportion of Treatment-Experienced Patients Who Achieved Viral Loads <50 Copies/mL at 24 Weeks

Placebo Once-Daily Maraviroc Twice-Daily Maraviroc
Overall 23% 44% 45%
Subgroup analyses
No active drugs in OBR 3% 18% 29%
Baseline CD4 count <50 cells/mm3 3% 11% 20%
Screening viral load ≥100,000 copies/mL 11% 28% 35%

OBR, optimized background regimen